ClinicalTrials.gg
RecruitingNCT06752668CRYSTAL-1Updated Apr 27, 2026

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

A Phase 2 interventional study of ORX750 and Placebo in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 37 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
3rd of 27
248 · median 100
Started
2024
with 3 others
Phase 2
10 of 30
3 open now
Primary completion
2026-12
later than 4 of 12 live
Registered
22nd of 30
by date
Lead sponsor
2 of 30
Centessa Pharmaceuticals (UK) Limited

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 22nd registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.

While all conditions result in feeling sleepy, there are some differences in other common symptoms:

  • NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
  • NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
  • IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up.

Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.

03

Conditions studied

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • ≥17 and ≤37 kg/m2
  • Meets the diagnostic criteria of Narcolepsy Type 1 (NT1), Type 2 (NT2) or Idiopathic Hypersomnia (IH) according to ICSD-3-TR criteria
  • Is willing and able to discontinue all medications used for the treatment of narcolepsy or idiopathic hypersomnia
  • Is willing and able to adhere to additional protocol requirements

Exclusion criteria

Exclusion Criteria:

  • A medical disorder other than NT1, NT2, or IH that is associated with excessive daytime sleepiness (EDS).
  • Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, , endocrine, neurological or psychiatric disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Narcolepsy Type 1: ORX750 and Placebo

    Drug: ORX750 · Drug: Placebo

  • Experimental
    Narcolepsy Type 2: ORX750 and Placebo

    Drug: ORX750 · Drug: Placebo

  • Experimental
    Idiopathic Hypersomnia: ORX750 and Placebo

    Drug: ORX750 · Drug: Placebo

Interventions

  • DrugORX750

    ORX750 capsule.

  • DrugPlacebo

    ORX750 matching placebo capsule.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Up to Day 35

  2. Number of Participants With Abnormal Changes From Baseline in Laboratory Tests

    Time frame: Up to Day 35

  3. Number of Participants With Abnormal Change From Baseline in Vital Signs

    Time frame: Up to Day 35

  4. Number of Participants With Abnormal Change From Baseline in Electrocardiograms (ECG)

    Time frame: Up to Day 35

  5. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 35

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for ORX750

    Time frame: Day 1, 15, 28

  2. Tmax: Time of Maximum Concentration for ORX750

    Time frame: Day 1, 15, 28

  3. AUC0last: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for ORX750

    Time frame: up to Day 28

  4. Cmax,ss: Maximum Observed Concentration at Steady State for ORX750

    Time frame: Day 1, 15, 28

  5. AUCτ: Area Under the Concentration-time Curve During a Dosing Interval at Steady State for ORX750

    Time frame: Day 1, 15, 28

  6. Mean sleep latency (average of the first 4 trials) in the Maintenance of Wakefulness Test (MWT) for ORX750 versus placebo.

    Mean sleep latency is determined by averaging the time to falling asleep across trials

    Time frame: Baseline up to Day 28

  7. Change From Baseline in Epworth Sleepiness Scale (ESS)

    Time frame: Baseline up to Day 28

07

Study locations

37 of 37 sites recruiting
  • Auburn, Alabama
    Auburn, Alabama 36832, United States
    Recruiting
  • Chandler, Arizona
    Chandler, Arizona 85224, United States
    Recruiting
  • Scottsdale, Arizona
    Scottsdale, Arizona 85253, United States
    Recruiting
  • Long Beach, California
    Long Beach, California 90805, United States
    Recruiting
  • Santa Ana, California
    Santa Ana, California 92705, United States
    Recruiting
  • Brandon, Florida
    Brandon, Florida 33511, United States
    Recruiting
  • Miami, Florida
    Miami, Florida 33155, United States
    Recruiting
  • Miami, Florida
    Miami, Florida 33176, United States
    Recruiting
  • Orlando, FL
    Orlando, Florida 32807, United States
    Recruiting
  • Winter Park, Florida
    Winter Park, Florida 32789, United States
    Recruiting
  • Atlanta, Georgia
    Atlanta, Georgia 30281, United States
    Recruiting
  • Atlanta, Georgia
    Atlanta, Georgia 30328, United States
    Recruiting
  • Riverdale, Georgia
    Riverdale, Georgia 30274, United States
    Recruiting
  • New Orleans, Louisiana
    New Orleans, Louisiana 70127, United States
    Recruiting
  • Newton, Massachusetts
    Newton, Massachusetts 02459, United States
    Recruiting
  • Southfield, Michigan
    Southfield, Michigan 48075, United States
    Recruiting
  • Sterling Heights, Michigan
    Sterling Heights, Michigan 48314, United States
    Recruiting
  • Henderson, Nevada
    Henderson, Nevada 89052, United States
    Recruiting
  • Denver, North Carolina
    Denver, North Carolina 28037, United States
    Recruiting
  • Huntersville, North Carolina
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Cincinnati, Ohio
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Cleveland, OH
    Cleveland, Ohio 44106, United States
    Recruiting
  • Dublin, Ohio
    Dublin, Ohio 43017, United States
    Recruiting
  • Willow Grove, Pennsylvania
    Willow Grove, Pennsylvania 19090, United States
    Recruiting
  • Columbia, South Carolina
    Columbia, South Carolina 29201, United States
    Recruiting
  • North Charleston, South Carolina
    North Charleston, South Carolina 29406, United States
    Recruiting
  • Austin, Texas
    Austin, Texas 78731, United States
    Recruiting
  • El Paso, TX
    El Paso, Texas 79912, United States
    Recruiting
  • San Antonio, Texas
    San Antonio, Texas 78229, United States
    Recruiting
  • Toronto, Ontario
    Toronto, Ontario M5S 3A3, Canada
    Recruiting
  • Leon, France
    Léon, Bordeaux 33000, France
    Recruiting
  • Bologna, Italy
    Bologna, 40139, Italy
    Recruiting
  • Pozzilli, Italy
    Pozzilli, 86077, Italy
    Recruiting
  • Verona, Italy
    Verona, 37134, Italy
    Recruiting
  • Madrid, Spain
    Madrid, 28036, Spain
    Recruiting
  • Madrid, Spain
    Madrid, 28043, Spain
    Recruiting
  • Vitoria-Gasteiz, Spain
    Vitoria-Gasteiz, 01009, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 31, 2024
StartActual
Dec 23, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752668
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Dec 23, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Centessa Pharmaceuticals
Contact
CRYSTAL-1@centessa.com
+1 617-468-5770

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion